nach oben

Neurological Sciences

Erschienen in:

17.11.2023 | Original Article

Real-world experience with Deutetrabenazine management in patients with Huntington’s disease using video-based telemedicine

verfasst von: Lishan Lin, Mansi Cai, Fengjuan Su, Tengteng Wu, Kang Yuan, Yucheng Li, Yue Luo, Dingbang Chen, Zhong Pei

Erschienen in: Neurological Sciences | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Huntington’s disease (HD) is a rare progressive neurological disorder, and telemedicine has the potential to improve the quality of care for patients with HD. Deutetrabenazine (DTBZ) can reduce chorea symptoms in HD; however, there is limited experience with this medication in Asian countries.

Methods

Retrospective and prospective studies were employed to explore the feasibility and reliability of a video-based telemedicine system for HD patient care. Reliability was demonstrated through consistency between selected-item scores (SIS) and total motor scores (TMS) and the agreement of scores obtained from hospital and home videos. Finally, a single-centre real-world DTBZ management study was conducted based on the telemedicine system to explore the efficacy of DTBZ in patients with HD.

Results

There were 77 patients included in the retrospective study, and a strong correlation was found between SIS and TMS (r = 0.911, P < 0.0001), indicating good representativeness. There were 32 patients enrolled in the prospective study. The reliability was further confirmed, indicated by correlations between SIS and TMS (r = 0.964, P < 0.0001) and consistency of SIS derived from the in-person and virtual visits (r = 0.969, P < 0.0001). There were 17 patients included in the DTBZ study with a mean 1.41 (95% confidence interval, 0.37–2.46) improvement in chorea score and reported treatment success.

Conclusions

A video-based telemedicine system is a feasible and reliable option for HD patient care. It may also be used for drug management as a supplementary tool for clinical visits.

Nur mit Berechtigung zugänglich

Leavitt BR, Kordasiewicz HB, Schobel SA (2020) Huntington-lowering therapies for Huntington disease: a review of the evidence of potential benefits and risks (vol 57, pg 612, 2020). Jama Neurol 77(8):1040. https://doi.org/10.1001/jamaneurol.2020.1973CrossRef

Abeyasinghe PM, Long JD, Razi A, Pustina D, Paulsen JS, Tabrizi SJ, Poudel GR, Georgiou-Karistianis N (2021) Tracking Huntington’s disease progression using motor, functional, cognitive, and imaging markers. Movement Disord 36(10):2282–2292. https://doi.org/10.1002/mds.28650CrossRefPubMed

Roos RA, Hermans J, Vegter-van der Vlis M, van Ommen GJ, Bruyn GW (1993) Duration of illness in Huntington’s disease is not related to age at onset. J Neurol Neurosurg Psychiatry 56(1):98–100. https://doi.org/10.1136/jnnp.56.1.98CrossRefPubMedPubMedCentral

Pringsheim T, Wiltshire K, Day L, Steeves T, Jette N (2012) The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Movement Disord J Movement Disord Soc 27(9):1083–1091. https://doi.org/10.1002/mds.25075CrossRef

Nakashima K, Watanabe Y, Kusumi M, Nanba E, Maeoka Y, Nakagawa M, Igo M, Irie H, Ishino H, Fujimoto A, Goto J, Takahashi K (1996) Epidemiological and genetic studies of Huntington’s disease in the San-in area of Japan. Neuroepidemiology 15(3):126–131. https://doi.org/10.1159/000109899CrossRefPubMed

Li HL, Li XY, Dong Y, Zhang YB, Cheng HR, Gan SR, Liu ZJ, Ni W, Burgunder JM, Yang XW, Wu ZY (2019) Clinical and genetic profiles in Chinese patients with Huntington’s disease: a ten-year multicenter study in China. Aging Dis 10(5):1003–1011. https://doi.org/10.14336/AD.2018.0911CrossRefPubMedPubMedCentral

Chang CM, Yu YL, Fong KY, Wong MT, Chan YW, Ng TH, Leung CM, Chan V (1994) Huntington’s disease in Hong Kong Chinese: epidemiology and clinical picture. Clin Exp Neurol 31:43–51PubMed

Chen YY, Lai CH (2010) Nationwide population-based epidemiologic study of Huntington’s disease in Taiwan. Neuroepidemiology 35(4):250–254. https://doi.org/10.1159/000319462CrossRefPubMed

Lin L, Su F, Chen D, Pei Z (2022) The first patient with sporadic Huntington’s disease due to a de novo (CAG)n expansion in China. J Transl Int Med 10(1):76–78. https://doi.org/10.2478/jtim-2022-0006CrossRefPubMedPubMedCentral

10.

Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JJ, Siemers E, Shoulson I (2000) Rate of functional decline in Huntington’s disease. Huntington Stud Group Neurol 54(2):452–458. https://doi.org/10.1212/wnl.54.2.452CrossRef

11.

Orth M, Handley OJ, Schwenke C, Dunnett S, Wild EJ, Tabrizi SJ, Landwehrmeyer GB (2011) Observing Huntington’s disease: the European Huntington’s disease network’s registry. J Neurol Neurosurg Psychiatry 82(12):1409–1412. https://doi.org/10.1136/jnnp.2010.209668CrossRefPubMed

12.

Ke HY, Cao X, Song YY, Cao L (2021) Health services utilization of Chinese patients with Huntington’s disease: a cross-sectional study. Bmc Health Serv Res 21(1). https://doi.org/10.1186/s12913-021-06826-1

13.

Schneider RB, Biglan KM (2017) The promise of telemedicine for chronic neurological disorders: the example of Parkinson’s disease. Lancet Neurol 16(7):541–551. https://doi.org/10.1016/S1474-4422(17)30167-9CrossRefPubMed

14.

Mustafa SS, Vadamalai K, Ramsey A (2021) Patient satisfaction with in-person, video, and telephone allergy/immunology evaluations during the COVID-19 pandemic. J Aller Cl Imm-Pract 9(5):1858–1863. https://doi.org/10.1016/j.jaip.2021.01.036CrossRef

15.

van der Hout A, van Uden-Kraan CF, Holtmaat K, Jansen F, Lissenberg-Witte BI, Nieuwenhuijzen G, Hardillo JA, de Jong R, Tiren-Verbeet NL, Sommeijer DW, de Heer K, Schaar CG, Sedee R, Bosscha K, van den Brekel M, Petersen JF, Westerman M, Honings J, Takes RP, Houtenbos I, van den Broek WT, de Bree R, Jansen P, Eerenstein S, Leemans CR, Zijlstra JM, Cuijpers P, van de Poll-Franse LV, Verdonck-De Leeuw IM (2020) Role of ehealth application oncokompas in supporting self-management of symptoms and health-related quality of life in cancer survivors: a randomised, controlled trial. Lancet Oncol 21(1):80–94. https://doi.org/10.1016/S1470-2045(19)30675-8CrossRefPubMed

16.

van der Kolk NM, de Vries NM, Kessels R, Joosten H, Zwinderman AH, Post B, Bloem BR (2019) Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson’s disease: a double-blind, randomised controlled trial. Lancet Neurol 18(11):998–1008. https://doi.org/10.1016/S1474-4422(19)30285-6CrossRefPubMed

17.

Dobkin RD, Mann SL, Gara MA, Interian A, Rodriguez KM, Menza M (2020) Telephone-based cognitive behavioral therapy for depression in Parkinson disease a randomized controlled trial. Neurology 94(16):E1764–E1773. https://doi.org/10.1212/WNL.0000000000009292CrossRefPubMedPubMedCentral

18.

Harrison MB, Morrissey D (2021) Interdisciplinary telemedicine services for Huntington’s disease: a 20-year experience. Telemed E-Health 27(5):583–586. https://doi.org/10.1089/tmj.2020.0316CrossRef

19.

Bull MT, Darwin K, Venkataraman V, Wagner J, Beck CA, Dorsey ER, Biglan KM (2014) A pilot study of virtual visits in huntington disease. J Huntingtons Dis 3(2):189–195. https://doi.org/10.3233/JHD-140102CrossRefPubMed

20.

Hu B (2019) Application of wearable technology in clinical walking and dual task testing. J Transl Int Med 7(3):87–89. https://doi.org/10.2478/jtim-2019-0019CrossRefPubMedPubMedCentral

21.

Tabrizi SJ, Estevez-Fraga C, van Roon-Mom W, Flower MD, Scahill RI, Wild EJ, Munoz-Sanjuan I, Sampaio C, Rosser AE, Leavitt BR (2022) Potential disease-modifying therapies for Huntington’s disease: lessons learned and future opportunities. Lancet Neurol 21(7):645–658. https://doi.org/10.1016/S1474-4422(22)00121-1CrossRefPubMedPubMedCentral

22.

Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O’Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora FJ, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, Mcgarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, Lafaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E (2016) Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA 316(1):40–50. https://doi.org/10.1001/jama.2016.8655CrossRefPubMed

23.

Savani AA, Login IS (2007) Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 68(10):797–797. https://doi.org/10.1212/01.wnl.0000259143.52138.5cCrossRefPubMed

24.

Huntington Study Group HART Investigators (2013) A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington’s disease. Mov Disord 28(10):1407–1415. https://doi.org/10.1002/mds.25362CrossRef

25.

Venuto CS, Mcgarry A, Ma Q, Kieburtz K (2012) Pharmacologic approaches to the treatment of Huntington’s disease. Movement Disord 27(1):31–41. https://doi.org/10.1002/mds.23953CrossRefPubMed

26.

Thorley EM, Iyer RG, Wicks P, Curran C, Gandhi SK, Abler V, Anderson KE, Carlozzi NE (2018) Understanding how chorea affects health-related quality of life in Huntington disease: an online survey of patients and caregivers in the United States. Patient 11(5):547–559. https://doi.org/10.1007/s40271-018-0312-xCrossRefPubMedPubMedCentral

27.

Mestre TA, Carlozzi NE, Ho AK, Burgunder JM, Walker F, Davis AM, Busse M, Quinn L, Rodrigues FB, Sampaio C, Goetz CG, Cubo E, Martinez-Martin P, Stebbins GT (2018) Quality of life in Huntington’s disease: critique and recommendations for measures assessing patient health-related quality of life and caregiver quality of life. Movement Disord 33(5):742–749. https://doi.org/10.1002/mds.27317CrossRefPubMed

28.

Heo YA, Scott LJ (2017) Deutetrabenazine: a review in chorea associated with Huntington’s disease. Drugs 77(17):1857–1864. https://doi.org/10.1007/s40265-017-0831-0CrossRefPubMed

29.

Cheng Y, Gu X, Liu K, Yang T, Xiao Y, Jiang Q, Huang J, Lin J, Wei Q, Ou R, Hou Y, Zhang L, Li C, Burgunder JM, Shang H (2022) The comprehensive analysis of motor and neuropsychiatric symptoms in patients with Huntington’s disease from China: a cross-sectional study. J Clin Med 12(1). https://doi.org/10.3390/jcm12010206

30.

Li XY, Gao B, Xie JJ, Bao YF, Dong Y, Wu ZY (2021) The clinical, imaging and biological features of psychosis in Han Chinese patients with Huntington’s disease. J Psychiatr Res 141:333–338. https://doi.org/10.1016/j.jpsychires.2021.07.024CrossRefPubMed

31.

Frank S, Testa C, Edmondson MC, Goldstein J, Kayson E, Leavitt BR, Oakes D, O’Neill C, Vaughan C, Whaley J, Gross N, Gordon MF, Savola JM (2022) The safety of deutetrabenazine for chorea in Huntington disease: an open-label extension study. CNS Drugs 36(11):1207–1216. https://doi.org/10.1007/s40263-022-00956-8CrossRefPubMedPubMedCentral

32.

Koch J, Shi WX, Dashtipour K (2020) Vmat2 inhibitors for the treatment of hyperkinetic movement disorders. Pharmacol Therapeut 212. https://doi.org/10.1016/j.pharmthera.2020.107580

33.

Bashir H, Jankovic J (2018) Deutetrabenazine for the treatment of Huntington’s chorea. Expert Rev Neurother 18(8):625–631. https://doi.org/10.1080/14737175.2018.1500178CrossRefPubMed

34.

Dean M, Sung VW (2018) Review of deutetrabenazine: a novel treatment for chorea associated with Huntington’s disease. Drug Des Dev Ther 12:313–319. https://doi.org/10.2147/DDDT.S138828CrossRef

35.

Ho AK, Gilbert AS, Mason SL, Goodman AO, Berker RA (2009) Health-related quality of life in Huntington’s disease: which factors matter most? Movement Disord 24(4):574–578. https://doi.org/10.1002/mds.22412CrossRefPubMed

36.

Frank S, Stamler D, Kayson E, Claassen DO, Colcher A, Davis C, Duker A, Eberly S, Elmer L, Furr-Stimming E, Gudesblatt M, Hunter C, Jankovic J, Kostyk SK, Kumar R, Loy C, Mallonee W, Oakes D, Scott BL, Sung V, Goldstein J, Vaughan C, Testa CM (2017) Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea. Jama Neurol 74(8):977–982. https://doi.org/10.1001/jamaneurol.2017.1352CrossRefPubMedPubMedCentral

37.

Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, Bega D, Ledoux MS, Shprecher DR, Anderson KE (2019) Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry 90(12):1317–1323. https://doi.org/10.1136/jnnp-2018-319918CrossRefPubMed

38.

Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojarvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, Mcevoy JP, Ochudlo S, Ondo WG, Fernandez HH (2017) Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (aim-td): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiat 4(8):595–604. https://doi.org/10.1016/S2215-0366(17)30236-5CrossRef

39.

Sorensen SA, Fenger K (1992) Causes of death in patients with Huntington’s disease and in unaffected first degree relatives. J Med Genet 29(12):911–914. https://doi.org/10.1136/jmg.29.12.911CrossRefPubMedPubMedCentral

40.

Edmonds C (1966) Huntington’s chorea, dysphagia and death. Med J Aust 2(6):273–274. https://doi.org/10.5694/j.1326-5377.1966.tb73569.xCrossRefPubMed

41.

Lanska DJ, Lavine L, Lanska MJ, Schoenberg BS (1988) Huntington’s disease mortality in the United States. Neurology 38(5):769–772. https://doi.org/10.1212/wnl.38.5.769CrossRefPubMed

Titel: Real-world experience with Deutetrabenazine management in patients with Huntington’s disease using video-based telemedicine
verfasst von: Lishan Lin
Mansi Cai
Fengjuan Su
Tengteng Wu
Kang Yuan
Yucheng Li
Yue Luo
Dingbang Chen
Zhong Pei
Publikationsdatum: 17.11.2023
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 5/2024
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-023-07179-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2024

Neuro-oncological research output in Africa: a scoping review of primary brain tumors

Clinical features and visual prognosis of very late-onset neuromyelitis optica spectrum disorder–related optic neuritis

Objective assessment of the effects of opicapone in Parkinson’s disease through kinematic analysis

Letter to the editor: Blurry vision as the initial symptom in Guillain-Barré syndrome: a case report

Bilateral delayed non-ischemic enhancing brain lesions after treatment with flow-diverter